Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Profit After Tax (2016 - 2025)

Corcept Therapeutics' Profit After Tax history spans 10 years, with the latest figure at $24.3 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 21.05% year-over-year to $24.3 million; the TTM value through Dec 2025 reached $99.6 million, down 29.44%, while the annual FY2025 figure was $99.7 million, 29.43% down from the prior year.
  • Profit After Tax for Q4 2025 was $24.3 million at Corcept Therapeutics, up from $19.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $47.2 million in Q3 2024 and bottomed at $15.9 million in Q1 2023.
  • The 5-year median for Profit After Tax is $27.6 million (2023), against an average of $28.0 million.
  • The largest annual shift saw Profit After Tax soared 89.13% in 2023 before it crashed 58.34% in 2025.
  • A 5-year view of Profit After Tax shows it stood at $32.1 million in 2021, then crashed by 48.2% to $16.6 million in 2022, then surged by 89.13% to $31.4 million in 2023, then dropped by 2.09% to $30.7 million in 2024, then dropped by 21.05% to $24.3 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Profit After Tax are $24.3 million (Q4 2025), $19.7 million (Q3 2025), and $35.1 million (Q2 2025).